HomeCIPLA › Filing
🔔 Get instant alerts when CIPLA files quarterly results on BSE Start free trial →
Cipla Limited (CIPLA)

Amalgamation/Merger

Filed: 19 Aug 2026, 17:01 IST Exchange: NSE Category: Merger/Acquisition — Amalgamation Approval
Cipla Limited received NCLT Mumbai order approving scheme to amalgamate wholly-owned subsidiary Inzpera Healthsciences Limited into Cipla. The scheme's appointed date is 01-Apr-2026. No shares will be issued as Inzpera is fully owned. Benefits include resource consolidation, cost savings, and improved cash management. Meetings of shareholders and creditors dispensed with due to consents. Notices to regulators and stakeholders mandated. No adverse financial impact expected post-amalgamation.
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 CIPLA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add CIPLA to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Cipla Limited

Important. The summary above is generated automatically from Cipla Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.